Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$104.32 +1.0%	$105.86	$75.56 ▼ $139.13	$5.15B	0.51	701,861 shs	411,762 shs
COGT Cogent Biosciences	$10.86 -1.0%	$9.13	$3.72 ▼ $12.97	$1.25B	0.36	2.63 million shs	1.73 million shs
CRSP CRISPR Therapeutics	$55.96 -0.7%	$51.22	$30.04 ▼ $71.13	$5.12B	1.8	3.78 million shs	1.90 million shs
LNTH Lantheus	$54.86 +5.8%	$76.68	$47.25 ▼ $118.21	$3.59B	0.14	1.73 million shs	3.90 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	+1.03%	+2.90%	-3.77%	-3.19%	+24.41%
COGT Cogent Biosciences	-1.00%	-4.90%	+11.04%	+124.38%	+25.84%
CRSP CRISPR Therapeutics	-0.67%	-0.53%	+2.08%	+57.10%	+18.38%
LNTH Lantheus	+5.76%	-22.94%	-33.43%	-32.98%	-42.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.8393 of 5 stars	4.5	3.0	4.5	3.1	4.2	0.6
COGT Cogent Biosciences	3.2303 of 5 stars	4.4	1.0	0.0	3.6	1.7	0.6
CRSP CRISPR Therapeutics	3.6797 of 5 stars	4.3	2.0	0.0	3.6	3.3	0.6
LNTH Lantheus	4.6129 of 5 stars	3.4	3.0	4.2	3.0	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.07	Buy	$178.00	70.63% Upside
COGT Cogent Biosciences	2.82	Moderate Buy	$18.70	72.19% Upside
CRSP CRISPR Therapeutics	2.50	Moderate Buy	$71.60	27.95% Upside
LNTH Lantheus	2.86	Moderate Buy	$114.50	108.71% Upside

Current Analyst Ratings Breakdown

Latest COGT, AXSM, LNTH, and CRSP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	COGT Cogent Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$29.00 ➝ $30.00
8/7/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $80.00
8/7/2025	LNTH Lantheus	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$112.00 ➝ $73.00
8/7/2025	LNTH Lantheus	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$120.00 ➝ $70.00
8/6/2025	COGT Cogent Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $21.00
8/6/2025	CRSP CRISPR Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$42.00 ➝ $56.00
8/5/2025	AXSM Axsome Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$173.00 ➝ $176.00
8/5/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$184.00 ➝ $189.00
8/5/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00
8/5/2025	CRSP CRISPR Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$38.00 ➝ $42.00
8/4/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$150.00

(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$385.69M	13.50	N/A	N/A	$1.46 per share	71.45
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$0.41 per share	N/A
CRSP CRISPR Therapeutics	$37.31M	136.41	N/A	N/A	$18.81 per share	2.98
LNTH Lantheus	$1.53B	2.47	$7.50 per share	7.31	$16.86 per share	3.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.07	N/A	36.99	N/A	-49.88%	-283.22%	-33.06%	N/A
COGT Cogent Biosciences	-$255.86M	-$1.78	N/A	N/A	N/A	N/A	-223.82%	-89.44%	N/A
CRSP CRISPR Therapeutics	-$366.25M	-$5.43	N/A	N/A	N/A	-1,229.43%	-20.05%	-17.09%	N/A
LNTH Lantheus	$312.44M	$3.52	14.59	8.69	N/A	17.82%	34.06%	19.10%	N/A

Latest COGT, AXSM, LNTH, and CRSP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	LNTH Lantheus	$1.65	$1.57	-$0.08	$1.12	$389.69 million	$378.05 million
8/5/2025	Q2 2025	COGT Cogent Biosciences	-$0.55	-$0.53	+$0.02	-$0.53	N/A	N/A
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.00	-$0.92	+$0.08	-$0.97	$140.02 million	$150.04 million
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.47	-$1.29	+$0.18	-$2.40	$6.44 million	$0.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	1.66	1.57	1.96
COGT Cogent Biosciences	N/A	4.19	5.13
CRSP CRISPR Therapeutics	N/A	16.61	15.64
LNTH Lantheus	0.49	4.29	5.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
COGT Cogent Biosciences	N/A
CRSP CRISPR Therapeutics	69.20%
LNTH Lantheus	99.06%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.30%
COGT Cogent Biosciences	7.29%
CRSP CRISPR Therapeutics	4.30%
LNTH Lantheus	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	49.90 million	38.77 million	Optionable
COGT Cogent Biosciences	80	113.86 million	105.56 million	Optionable
CRSP CRISPR Therapeutics	460	90.95 million	87.04 million	Optionable
LNTH Lantheus	700	69.19 million	68.15 million	Optionable

COGT, AXSM, LNTH, and CRSP Headlines

Recent News About These Companies

Lantheus (NASDAQ:LNTH) Hits New 1-Year Low - Should You Sell?

August 7 at 12:27 PM | marketbeat.com

Lantheus Reports Second Quarter 2025 Financial Results and Provides Business Update

August 7 at 6:41 AM | taiwannews.com.twT

Lantheus announces FDA review for new radioactive imaging agent

August 7 at 6:41 AM | msn.com

Why Lantheus (LNTH) Stock Is Falling Today

August 7 at 6:41 AM | msn.com

Lantheus Holdings (LNTH) Announces US$400 Million Buyback Amid FDA and Earnings Updates

August 7 at 6:41 AM | finance.yahoo.com

Lantheus (NASDAQ:LNTH) Reports Sales Below Analyst Estimates In Q2 Earnings, Stock Drops 20.8%

August 7 at 6:41 AM | finance.yahoo.com

Cetera Investment Advisers Grows Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

August 7 at 3:16 AM | marketbeat.com

Lantheus Holdings, Inc. (LNTH) Q2 2025 Earnings Call Transcript

August 6 at 10:06 PM | seekingalpha.com

Lantheus Holdings: Reassessing The Buy Thesis

August 6 at 10:09 AM | seekingalpha.com

Lantheus Announces FDA Acceptance of NDA for New Formulation for Market-Leading PSMA PET Imaging Agent

August 6 at 6:45 AM | globenewswire.com

Lantheus Holdings Q2 2025 Earnings Preview

August 5 at 4:54 PM | msn.com

Lantheus (LNTH) Reports Q2: Everything You Need To Know Ahead Of Earnings

August 5 at 11:53 AM | msn.com

Lantheus Holdings Inc (LNTH) Q2 2025: Everything You Need To Know Ahead Of Earnings

August 5 at 11:53 AM | finance.yahoo.com

Lantheus Holdings, Inc. (NASDAQ:LNTH) Stake Boosted by Westfield Capital Management Co. LP

August 5 at 7:44 AM | marketbeat.com

Allianz SE Has $772,000 Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

August 5 at 7:10 AM | marketbeat.com

Jupiter Asset Management Ltd. Invests $5.74 Million in Lantheus Holdings, Inc. (NASDAQ:LNTH)

August 5 at 6:46 AM | marketbeat.com

LSV Asset Management Has $36.17 Million Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

August 5 at 6:46 AM | marketbeat.com

Lantheus (LNTH) Projected to Post Earnings on Wednesday

August 5 at 2:23 AM | americanbankingnews.com

Lantheus Holdings (NASDAQ:LNTH) shareholders have earned a 39% CAGR over the last five years

August 4, 2025 | finance.yahoo.com

Phocas Financial Corp. Cuts Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

August 4, 2025 | marketbeat.com

29,530 Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH) Purchased by Jefferies Financial Group Inc.

August 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

COGT, AXSM, LNTH, and CRSP Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$104.32 +1.06 (+1.03%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$103.96 -0.36 (-0.35%)

As of 08/7/2025 05:55 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Cogent Biosciences NASDAQ:COGT

$10.86 -0.11 (-1.00%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$11.00 +0.14 (+1.29%)

As of 08/7/2025 05:14 PM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

CRISPR Therapeutics NASDAQ:CRSP

$55.96 -0.38 (-0.67%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$56.30 +0.34 (+0.61%)

As of 04:21 AM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Lantheus NASDAQ:LNTH

$54.86 +2.99 (+5.76%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$54.96 +0.10 (+0.18%)

As of 04:07 AM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time